Drug details

Kynmobi (apomorphine hydrochloride sublingual film)

type of Antiparkinson Agents, Dopamine Agonists

Kynmobi (apomorphine hydrochloride) is a non-ergoline dopamine agonist indicated for the acute, intermittent
treatment of "off" episodes in patients with Parkinson's disease

This drug may have the following side effects:

• redness
• pain
• swelling
• confusion
• allergic reactions. See the “Do not take Kynmobi if you are”
  section.
• mouth sores (ulceration)
• dryness of the mouth, lips or tongue
• pain with swallowing
• very high fever
• stiff muscles
• changes in breathing and heartbeat

The following drugs are related to Kynmobi, either as a replacement or used together:

• Osmolex ER (amantadine)
• Gocovri (amantadine extended release capsules, for oral use)
• Symmetrel (amantadine hydrochloride)
• Apokyn (apomorphine)
• Artane (trihexyphenidyl)
• Azilect (rasagiline)
• Cogentin (benztropine mesylate injection)
• Rytary (carbidopa and levodopa capsules)
• Duopa (carbidopa and levodopa enteral suspension)
• Parcopa (carbidopa and levodopa extended-release tablets)
• Stalevo (carbidopa, levodopa and entacapone)
• Sinemet (carbidopa-levodopa)
• Sinemet CR (carbidopa-levodopa sustained release)
• Comtan (entacapone)
• Eldepryl (selegiline hcl)
• Inbrija (levodopa inhalation powder)
• Nourianz (istradefylline tablets)
• Mirapex (pramipexole)
• Mirapex ER (pramipexole dihydrochloride extended-release tablets)
• Neupro (rotigotine transdermal system)
• Ongentys (opicapone capsules)
• Requip (ropinirole hcl)
• Requip XL (ropinirole extended release tablets)
• Xadago (safinamide tablets)
• Zelapar (selegiline hydrochloride)
• Tasmar (tolcapone)